AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02720523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet; Oral
Study NCT01802593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZATHIOPRINE or METHOTREXATE
Description: Patients should continue azathioprine or 6 MP or methotrexate at their previous doses for 6 months IMM therapy 26 weeks
Study NCT01802593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZATHIOPRINE or METHOTREXATE
Description: Patients should continue the same dose of azathioprine or 6 MP or methotrexate until the day of the second infusion (week 2)~Thiopurine therapy 2 weeks
Study NCT00791050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allon Thermowrap. MTRE Advanced Technologies Ltd.
Description: Thermowrap set at 37 °C before induction of anesthesia and maintained until initiation of CPB; during CPB set to monitoring and set again to 37 °C from rewarming during CPB to end of surgery.
Study NCT02191280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antistax®, low dose
Study NCT02191280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antistax®, high dose
Study NCT02929199 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: All ceramic crown
Description: Pressed E-Max coping veneered with E-max veneering system
Study NCT02929199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid crown
Description: pressed Bio HPP veneered with Visio-Lign Veneering system
Study NCT02191280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00292071 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: caspofungin acetate
Description: (50 mg/m²/day and 70 mg/m²/day) Caspofungin will be given for a minimum of 4 days (or at least 2 separate days of 7-point plasma sampling). Patients will be administered caspofungin for a maximum of 28 days.
Study NCT00289289 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention Pacing Features
Description: Intervention pacing features (atrial rate stabilization algorithm, atrial preference pacing algorithm, post mode switch overdrive pacing algorithm) in the pacemaker.
Study NCT03711370 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clear Bottle
Description: These mothers received usual care from their pediatric providers and each mother was given 12 conventional, clear bottles of various sizes (4-12 ounces) that were compatible with a variety of different nipples manufactured by leading bottle companies. Mothers were also given handouts about proper formula preparation and paced bottle-feeding, which included messages about feeding in response to infant cues.
Study NCT01930240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRIA-662
Description: 1-MNA Chloride
Study NCT03711370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opaque Bottle
Description: These mothers received everything provided to the clear group, but instead received 12 opaque bottles of various sizes (4-12 ounces). These bottles were stainless steel and compatible with a variety of different nipples manufactured by a leading bottle company. Mothers in the intervention group also received an additional handout that contained safety tips for their opaque bottles (e.g., never microwave your bottle).
Study NCT01270880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hsp90 inhibitor STA-9090
Description: Given IV
Study NCT01270880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01270880 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies
Study NCT01270880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies
Study NCT01270880 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RNA analysis
Description: Correlative studies
Study NCT01270880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spectrophotometry
Description: Correlative studies
Study NCT01270880 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Correlative studies
Study NCT01270880 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies
Study NCT01541735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: The pantoprazole will be administered in capsules of 40mg. The dose will be 1 capsule per day during 45 days.
Study NCT01541735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo 40 mg dose.
Study NCT00918606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIPO-102
Description: LIPO-102
Study NCT04810364 — intervention group
Intervention type: RADIATION
Intervention: Quantitative coronary angiography, intravascular imaging with percutaneous intervention
Description: Coronaries will be shot with AXIOM Artis dFC (Siemens, Munich,Germany) or systems from any other vendors. In case if necessary the procedure will be delayed for intravascular imaging (OCT, IVUS, VH-IVUS, NIRS) and/ or percutaneous intervention (with implantation of the medical device).
Study NCT00182078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo was administered for 24 weeks on a flexible fixed schedule beginning at 25mg per day, and increasing as high as 150 mg/day. Both groups received the assigned medication and dose over a 24-week period. At Week 12, the placebo was tapered at a rate of 25mg every 3 days until it was discontinued.
Study NCT00182078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: The drugs were administered for 24 weeks on a flexible fixed schedule beginning at 25mg per day, and increasing as high as 150 mg/day. Both groups received the assigned medication and dose over a 24-week period. At Week 12, the medication was tapered at a rate of 25mg every 3 days until it was discontinued.
Study NCT01679678 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PolyHeal 2
Description: PolyHeal is a sterile medical device
Study NCT01679678 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polyheal
Description: PolyHeal is a sterile medical device that is comprised of negatively charged 5-micron polystyrene microspheres suspended in
Study NCT01473199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioPoly RS Partial Resurfacing Knee Implant
Description: A long term, surgically invasive device for replacement of focal osteochondral defects in the weight bearing region of the femoral condyles.
Study NCT00229697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Study NCT01930240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blind placebo
Study NCT01031199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 FEDAA1106 (BAY85-8101)
Description: MS/CIS patients: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer \< 5 µg, PET
Study NCT00229697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Study NCT00229697 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tamoxifen
Study NCT03180333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNA
Study NCT03180333 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PNA placebo
Study NCT04042597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: anlotinib was given at a fixed dose of 12mg D1-14 every 21 days
Study NCT04042597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anlotinib Hydrochloride
Description: anlotinib was given at a fixed dose of 12mg D1-14 every 21 days
Study NCT04685980 — intervention group
Intervention type: PROCEDURE
Intervention: spinal anaesthesia with local anaesthetic and intrathecal morphine
Description: Patients undergoing cesarean delivery and received spinal anaesthesia with local anaesthetic and intrathecal morphine
Study NCT01527591 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pneumococcal Conjugate Vaccine 13 (PCV13)
Description: A single intramuscular dose of 0.5 mL.
Study NCT03027518 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: WILD 5 Wellness
Description: Participants will be asked to voluntarily engage in integrated, prescriptive, and trackable wellness interventions combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.
Study NCT01373008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled extra-fine hydrofluoalkane-beclomethasone (QVAR)
Description: Infants will be randomized for Inhaled QVAR 100 microgram or placebo twice daily with spontaneous tidal breathing for 30 seconds via aerochamber with face mask for the study period.
Study NCT01031199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 FEDAA1106 (BAY85-8101)
Description: Healthy controls: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer \< 5 µg, PET
Study NCT00964262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR Exenatide (PT302)
Description: 0.5 mg, 1.0 mg, 2.0 mg and 4.0 mg dosage(dose escalation), single subcutaneous injection
Study NCT00964262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Plcacebo of each doasage, single subcutanoeus injection
Study NCT00612339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin and Temozolomide
Description: This is Phase II study with the combination of Avastin \& Temozolomide for unresectable or multifocal WHO grade IV malignant glioma patients. Patients will receive up to 4 cycles of Avastin \& Temozolomide . Avastin administered at 10 mg/kg every 14 days beginning minimum of 7 days after biopsy or 28 days after craniotomy. Temozolomide will be dosed at 200 mg/m2 daily x 5 days in 28-day cycle. Patients will have baseline MRI \& repeat MRI every 4 weeks. If there is no evidence of disease progression after each cycle, or unacceptable toxicity, or as determined by investigators, patient non-compliance or patient withdraws consent to continue therapy \& requests discontinuation, patients will receive up to 4 cycles of Avastin \& Temozolomide, then proceed with standard XRT therapy, \& future therapy after 4 cycles will be at discretion of patient \& treating physicians.
Study NCT00740363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: Once daily sitagliptin. If GFR>50 ml/min/1.73m2: 100 mg/day. If GFR from 25 to 49 ml/min/1.3m2: 50 mg/day
Study NCT01373008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled extra-fine hydrofluoalkane-beclomethasone (QVAR)
Description: Infants will be randomized for Inhaled QVAR 100 microgram or placebo twice daily with spontaneous tidal breathing for 30 seconds via aerochamber with face mask for the study period.
Study NCT01831466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib ointment 20 mg/g
Description: tofacitinib ointment 20 mg/g BID (twice daily) for 12 weeks
Study NCT01831466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib ointment 10 mg/g
Description: tofacitinib ointment 10 mg/g BID (twice daily) for 12 weeks
Study NCT01831466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo ointment (vehicle)
Description: placebo ointment (vehicle) BID (twice daily) for 12 weeks
Study NCT01831466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib ointment 20 mg/g
Description: tofacitinib ointment 20 mg/g QD (once daily) for 12 weeks
Study NCT01831466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib ointment 10 mg/g
Description: tofacitinib ointment 10 mg/g QD (once daily) for 12 weeks
Study NCT01831466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo ointment (vehicle)
Description: placebo ointment (vehicle) QD (once daily) for 12 weeks
Study NCT03601065 — intervention group
Intervention type: OTHER
Intervention: Videos of polyps, resection of polyps
Description: Ther is no study specific intervention. Video sequences will be taken if polyps are found in the colon. Polyps will then be resected routinely.
Study NCT06291337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhibition of Sweet Taste by Ibuprofen Oral Rinses
Description: Participants rinse the mouth with ibuprofen and the impact on perceived sweet taste elicited by sugar solutions in the mouth was assessed
Study NCT06291337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhibition of Sweet Taste by Naproxen Oral Rinses
Description: Participants rinse the mouth with naproxen and the impact on perceived sweet taste elicited by sugar solutions in the mouth was assessed
Study NCT02282072 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation：PINS Stimulation System
Study NCT02282072 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep brain stimulation：PINS Stimulation System
Study NCT00475085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aprepitant
Description: Given orally or IV
Study NCT00475085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Given orally or IV
Study NCT00475085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally or IV
Study NCT00475085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granisetron hydrochloride
Description: Given orally or IV
Study NCT00475085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: palonosetron hydrochloride
Description: Given orally or IV
Study NCT00475085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron hydrochloride
Description: Given orally or IV
Study NCT00475085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prochlorperazine
Description: Given orally or IV
Study NCT00475085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prochlorperazine
Description: Given orally or IV
Study NCT00475085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT00475085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally
Study NCT04249297 — intervention group
Intervention type: DRUG
Intervention: Duphaston® (Dydrogesteron)
Description: No intervention. Description of routine practice only. Prescribed Duphaston® according local marketing authorization and international and Russian In-Vitro Fertilization guidelines for luteal phase support as part of an Assisted Reproductive Technology (1 tablet 3 times a day starting at the day of oocyte retrieval).
Study NCT04368299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Videoconferencing for follow-up
Study NCT04368299 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard in-person outpatient follow-up
Study NCT04087941 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: VM-202
Description: VM202 is a DNA plasmid that contains novel genomic cDNA hybrid human hepatocyte growth factor (HGF) coding sequence (HGF-X7) expressing two isoforms of HGF, HGF 728 and HGF 723.
Study NCT04087941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM-202
Description: VM202 is a DNA plasmid that contains novel genomic cDNA hybrid human hepatocyte growth factor (HGF) coding sequence (HGF-X7) expressing two isoforms of HGF, HGF 728 and HGF 723.
Study NCT03593486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level Pulsed EMF
Description: Low-level pulsed electromagnetic field stimulator delivered through a Helmholtz coil positioned around the participant's head and neck. Stimulation parameters are 0.032 µG at 0.89 Hz for 60 minutes.
Study NCT03593486 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: The stimulator will be placed around the participant's head and neck, but no EMF will be delivered.
Study NCT02010242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GKT137831
Description: 1 capsule of 100 mg twice a day for the first 6 weeks of treatment, and 2 capsules of 100 mg twice a day for next 6 weeks of treatment
Study NCT02010242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule of Placebo, twice a day, oral treatment self-administered by the patient for the 12 weeks of treatment.
Study NCT03939338 — intervention group
Intervention type: OTHER
Intervention: Treg levels and CMR results
Description: This is an observational study. Exposure: Different Treg levels and CMR results.
Study NCT03102515 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: USG-TAP block
Study NCT03102515 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CIC
Study NCT00293228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Isoniazid (5mg per kg up to 300 mg daily for 6 months)
Study NCT00293228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Isoniazid (5mg per kg up to 300 mg daily for 6 months)
Study NCT00740363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: No active sitagliptin treatment for 4 weeks
Study NCT00293228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoniazid
Description: isoniazid (5mg per kg up to 300 mg daily for 6 months
Study NCT00293228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isoniazid
Description: isoniazid (5mg per kg up to 300 mg daily for 6 months
Study NCT00851890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: 50 mg capsules
Study NCT00786500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gynostemma pentaphyllum tea
Description: 3 grams twice daily, orally
Study NCT00786500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tea
Description: 3 grams twice daily, orally
Study NCT03473977 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab (anti-IL5Ra) will be injected every 4 weeks in doses of 30 mg (total of 3 injections) in subjects with active Eosinophilic Gastritis.
Study NCT00851890 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABT-333
Description: Capsule
Study NCT00851890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon
Description: Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
Study NCT00851890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated interferon
Description: Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
Study NCT00851890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
Study NCT00851890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: 200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
Study NCT03687775 — intervention group
Intervention type: OTHER
Intervention: Stability assessment
Description: Qualitative and quantitative stability assessment
Study NCT02134561 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: psychological interview
Study NCT02134561 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: MRI
Description: This MRI is a specific intervention assign to the subjects of the study, that's why it is an interventionnal study
Study NCT02134561 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cognitive tests
Study NCT02134561 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: neurological tests
Study NCT02457689 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GTU®-MultiHIV B Clade Vaccine
Description: The investigational HIV-1 vaccine GTU®-MultiHIV B clade encodes for a MultiHIV antigen (synthetic fusion protein) built up by full-length polypeptides of Rev, Nef, Tat, p17 and p24 with more than 20 Th and CTL epitopes of protease, reverse transcriptase (RT) and gp160 regions of an HAN2 HIV-1 B clade isolate.
Study NCT02457689 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride BP
Description: For use in prophylactic and replacement therapy, requiring the use of isotonic saline solution.
Study NCT03519724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Reversal of deep NMB
Study NCT03519724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Reversal of moderate NMB
Study NCT00945568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminoleban EN
Description: benefits of this drug for patients who undergoing liver resection for HCC
Study NCT00945568 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Aminoleban EN
Description: benefits of this drug for patients who undergoing liver resection for HCC
Study NCT02628600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAI 590 mg
Description: LAI 590 mg QD: administered by inhaling drug product that had been aerosolized in an investigational eFlow nebulizer over approximately 14 minutes